-
Mashup Score: 19
Abstract. Purpose: Minimal residual disease (MRD) detection identifies patients with colorectal adenocarcinoma (CRC) likely to recur following definitive treatment. We evaluated a plasma only MRD assay to predict recurrence and survival in metastatic CRC patients undergoing curative intent procedures (surgery and/or radiotherapy), with or without (neo)adjuvant chemotherapy. The primary objective of this study was to assess the correlation of post-procedure tumor cfDNA detection status with radiographic disease recurrence (RFS). Experimental Design: Pre- and post-procedure longitudinal samples were collected from 53 patients and analyzed with a multiomic MRD assay detecting circulating tumor DNA (ctDNA) from genomic and epigenomic signals. Pre- and post-procedure ctDNA detection correlated with recurrence-free and overall survival. Results: 230/233 samples from 52 patients were successfully analyzed. At the time of data cutoff, 36 (69.2%) patients recurred with median follow-up of 31 mo
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Guiding Principles for Community Building in Global Oncology - 7 day(s) ago
With the escalating incidence and prevalence of cancer worldwide disproportionately affecting low- and middle-income countries, there is an urgent need for the global oncology community to foster bidirectional partnerships and an equitable exchange of knowledge, resources, and expertise. A dedicated Global Oncology Community of Practice (CoP) can serve as a self-organizing, grassroots approach for members, with common goals and values, to coordinate efforts, maximize impact, and ensure sustainable outcomes. It is imperative, however, when outlining goals and priorities to adhere to an ethical and appropriate framework during community building efforts to avoid perpetuating inequities and power imbalances. This article reviews the core guiding principles for ASCO’s Global Oncology CoP which includes responsibility, amplification, accessibility, sustainability, and decolonization.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
How a surprise diagnosis led him to found a youth basketball nonprofit.
Source: www.today.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 14Teacher Recalls Her First And Only Symptom Of Colon Cancer At 36 - 2 month(s) ago
What she thought was a stomach bug turned out to be cancer.
Source: www.today.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 68‘Where you live shouldn't determine how you get cancer’: An oncologist on global disparities - 4 month(s) ago
Cancer cases around the world are expected to surge 77% by 2050. A new WHO report highlights the disparities in mortality rates depending on income.
Source: www.statnews.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Patient-Reported Outcomes, Tumor Markers, and Survival Outcomes in Advanced GI Cancer - 6 month(s) ago
This cohort study examines the association of 1-month changes in patient-reported outcomes and serum tumor markers with treatment response and survival among patients with gastrointestinal cancer.
Source: jamanetwork.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
Overview The NCI’s Cancer Diagnosis Program in the Division of Cancer Treatment and Diagnosis is hosting a workshop on circulating tumor DNA (ctDNA) in cancer treatment and clinical care. Previously, a workshop was held in 2016focused on promoting the translation of ctDNA assays into clinical research. In the intervening years, much progress has been made in the fast-evolving field of ctDNA, and clinical utility has been demonstrated.
Source: events.cancer.govCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 8Immunosuppressive niche engineering at the onset of human colorectal cancer - Nature Communications - 1 year(s) ago
Integration of mathematical modeling, ecological analyses of patient biopsies, and neoantigen heterogeneity suggests recruitment of immunosuppressive cells is key to initializing transformation from adenoma to carcinoma in human colorectal cancer.
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer - 1 year(s) ago
Colorectal cancers express abundant viral-like repeat elements that can be targeted by nucleoside reverse transcriptase inhibitors in preclinical models, which was further translated into a phase II clinical trial.
Categories: Hem/Oncs, Latest HeadlinesTweet-
Thrilled to contribute @davetingmgh @KlempnerSam to this large collaboration.We’ve been interested in ORF1p in #crcsm though as shown here, perhaps more imminently useful in other tumors.transposons are fascinating. our https://t.co/8hcHLZnjwK trying to therapeutically exploit! https://t.co/KkFjkAcVZp
-
-
Mashup Score: 2The emerging promise of liquid biopsies in solid tumors - 1 year(s) ago
Liquid biopsies of circulating tumor DNA offer a non-invasive tool with many potential applications in oncology, including early cancer detection, profiling, disease prognosis, prediction of therapy response and monitoring disease status. A growing body of literature and clinical trials support an increasingly valuable role for liquid biopsies in the care of patients with solid malignancies.
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
As we started in 17, novelty not there but highlights a patient segment (oligomet CRC/ctDNA +) that needs options. Stay tuned for something we’re working on to broaden access to MRD trials! Plasma only (early version of guardant assay) in Oligomet CRC https://t.co/8jSXYs2Moz